Scarica l'app Stockscreener
26.43
2.24%
0.58
Dopo l'orario di chiusura:
26.39
-0.04
-0.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.85
Aprire:
$25.82
Volume 24 ore:
60.13M
Relative Volume:
0.89
Capitalizzazione di mercato:
$150.27B
Reddito:
$62.79B
Utile/perdita netta:
$9.84B
Rapporto P/E:
15.41
EPS:
1.7156
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+2.56%
1M Prestazione:
+5.47%
6M Prestazione:
+7.70%
1 anno Prestazione:
+3.32%
Intervallo 1D:
$25.81
$26.65
Intervallo di 1 settimana:
$25.13
$26.65
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.43 | 146.98B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,062.19 | 919.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
214.17 | 509.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.45 | 394.69B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.19 | 254.37B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.26 | 248.95B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open - ts2.tech
Pfizer (NYSE:PFE) Stock Price Up 2.3% After Dividend Announcement - MarketBeat
Pfizer (PFE) Valuation Check After Positive Phase 3 Wins and New Obesity Drug Licensing Deal - simplywall.st
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025 - ts2.tech
What's Going On With Pfizer Stock Monday?Pfizer (NYSE:PFE) - Benzinga
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com
Adaptive Biotechnologies inks two agreements with Pfizer in immunology By Investing.com - Investing.com UK
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com Canada
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies announces two immune receptor licensing agreements with Pfizer - PharmaLive
Adaptive Biotechnologies signs two immune receptor licensing deals with Pfizer - marketscreener.com
Watts Gwilliam & Co. LLC Buys 50,744 Shares of Pfizer Inc. $PFE - MarketBeat
Adaptive Biotechnologies Signs Target Discovery, Licensing Deals With Pfizer - marketscreener.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
ANALYSIS: Novo’s Novel GLP-1 Bid Failed But That’s Not the Point - Bloomberg Law News
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - marketscreener.com
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer - Yahoo Finance
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025) - ts2.tech
Pfizer’s Hold Rating: Navigating Loss of Exclusivity and Flat Growth Prospects - TipRanks
47,996 Shares in Pfizer Inc. $PFE Acquired by MASTERINVEST Kapitalanlage GmbH - MarketBeat
Marex Group plc Purchases Shares of 65,461 Pfizer Inc. $PFE - MarketBeat
Will Dogecoin Reach $1 By the End of the Year? - The Motley Fool
Pfizer Declares First-Quarter 2026 Dividend - BioSpace
Cullen Capital Management LLC Has $88.32 Million Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next - ts2.tech
Pfizer Stock (PFE) Before Market Open Dec. 15, 2025: Key News, 2026 Guidance Call, Analyst Targets, Dividend, and Risks - ts2.tech
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Orion Porfolio Solutions LLC Has $17.19 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025) - ts2.tech
Evergreen Capital Management LLC Purchases 63,611 Shares of Pfizer Inc. $PFE - MarketBeat
Forget Teladoc and Buy This Healthcare Stock Instead - Yahoo Finance
Bellevue Group AG Reduces Holdings in Pfizer Inc. $PFE - MarketBeat
Banque Transatlantique SA Lowers Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Adage Capital Partners GP L.L.C. - MarketBeat
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA “Black Box” Headline, Analyst Forecasts — What to Know Before the Next Market Open - ts2.tech
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open - ts2.tech
Pfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026 - marketscreener.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 - Investing.com
Pfizer declares $0.43 quarterly dividend payable in March 2026 By Investing.com - Investing.com Canada
Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. - The Globe and Mail
The Best Turnaround Stock to Invest $1,000 in Right Now - Finviz
Is Pfizer Shifting From Defensive Stock To Value Opportunity After Post Pandemic Restructuring? - simplywall.st
Treasurer of the State of North Carolina Purchases 520,580 Shares of Pfizer Inc. $PFE - MarketBeat
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial - Reuters
NewEdge Advisors LLC Acquires 97,789 Shares of Pfizer Inc. $PFE - MarketBeat
Morgan Stanley Adjusts Price Target on Pfizer to $28 From $32, Maintains Equalweight Rating - marketscreener.com
CIBC Asset Management Inc Trims Stock Position in Pfizer Inc. $PFE - MarketBeat
Camber Capital Management LP Has $36.36 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. - Britannica
Bayesian Capital Management LP Sells 55,000 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.51%
2.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):